State Street’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

State Street’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,007,380	Closed	-$257K	–	4821
2023 Q1	$257K	Sell	1,007,380 -22,498	-2%	-$20.3K	﹤0.01%	3974
2022 Q4	$1.22M	Buy	1,029,878 +106,866	+12%	+$225K	﹤0.01%	3517
2022 Q3	$1.88M	Buy	923,012 +610,984	+196%	+$1.04M	﹤0.01%	3435
2022 Q2	$481K	Buy	312,028 +233,313	+296%	+$912K	﹤0.01%	3836
2022 Q1	$398K	Buy	+78,715	New	+$358K	﹤0.01%	4137

State Street's PEAR Position: Q2 2023 in Review

State Street sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 1,007,380 shares — an estimated $257K sold.

State Street first reported a position in PEAR in Q1 2022 and held it in 5 quarters. The position peaked at $1.88M in Q3 2022. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

State Street reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
State Street sold 1,007,380 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $257K.
State Street first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q1 2022 and held it in 5 quarters.
State Street's Pear Therapeutics, Inc. Class A Common Stock position peaked at $1.88M in Q3 2022.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on State Street's 13F filing for Q2 2023, filed 14 Aug 2023.